Table of Content

Introduction
Global Markets Direct Report Coverage
sopharyngitis (Common Cold) - Overview
sopharyngitis (Common Cold) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
sopharyngitis (Common Cold) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
sopharyngitis (Common Cold) - Companies Involved in Therapeutics Development
Adare Pharma Solutions
Charleston Laboratories Inc
Eurofarma Laboratorios SA
Firebrick Pharma Pty Ltd
Pfizer Inc
SaNOtize Research and Development Corp
SSP Co Ltd
Tris Pharma Inc
sopharyngitis (Common Cold) - Drug Profiles
(acetaminophen + fexofedine + phenylephrine) - Drug Profile
Product Description
Mechanism Of Action
guaifenesin ER - Drug Profile
Product Description
Mechanism Of Action
History of Events
hydrocodone bitartrate + Undisclosed drug - Drug Profile
Product Description
Mechanism Of Action
IMP-1088 - Drug Profile
Product Description
Mechanism Of Action
NORS-1002 - Drug Profile
Product Description
Mechanism Of Action
ORB-110 - Drug Profile
Product Description
Mechanism Of Action
History of Events
povidone iodine - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit MAPK13 for Asthma and Cold - Drug Profile
Product Description
Mechanism Of Action
ST-HT - Drug Profile
Product Description
Mechanism Of Action
History of Events
TRN-123 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TRN-124 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TRN-125 - Drug Profile
Product Description
Mechanism Of Action
History of Events
sopharyngitis (Common Cold) - Dormant Projects
sopharyngitis (Common Cold) - Discontinued Products
sopharyngitis (Common Cold) - Product Development Milestones
Featured News & Press Releases
Jul 01, 2015: Spriaso Announces Approval of New Drug Application for the Long Acting Codeine Antitussive With a Popular Anti-Histamine
Oct 10, 2013: Spriaso completes FDA Meeting on Tuxarin ER
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Nasopharyngitis (Common Cold), 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Nasopharyngitis (Common Cold), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Nasopharyngitis (Common Cold) - Pipeline by Adare Pharma Solutions, 2022
Nasopharyngitis (Common Cold) - Pipeline by Charleston Laboratories Inc, 2022
Nasopharyngitis (Common Cold) - Pipeline by Eurofarma Laboratorios SA, 2022
Nasopharyngitis (Common Cold) - Pipeline by Firebrick Pharma Pty Ltd, 2022
Nasopharyngitis (Common Cold) - Pipeline by Pfizer Inc, 2022
Nasopharyngitis (Common Cold) - Pipeline by SaNOtize Research and Development Corp, 2022
Nasopharyngitis (Common Cold) - Pipeline by SSP Co Ltd, 2022
Nasopharyngitis (Common Cold) - Pipeline by Tris Pharma Inc, 2022
Nasopharyngitis (Common Cold) - Dormant Projects, 2022
Nasopharyngitis (Common Cold) - Discontinued Products, 2022